2012
DOI: 10.21256/zhaw-3446
|View full text |Cite
|
Sign up to set email alerts
|

The cost and revenue situation of intravenous administration versus subcutaneous application of Herceptin and MabThera in Switzerland

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles